Phase 1 clinical trial of LFD-200 in Rheumatoid Arthritis is ongoing; Enrolling and dosing is underway

News & Events

NEWS

November 18, 2025

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors

October 27, 2025

Lifordi Immunotherapeutics Presents Nonclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 at ACR 2025 and Initiates Phase 1 Study in Rheumatoid Arthritis

October 10, 2025

Lifordi Immunotherapeutics to Present New Preclinical Data on Antibody Drug Conjugate LFD-200 Demonstrating Selective and Sustained Delivery of Glucocorticoid Payload to Immune Tissues Without Evidence of Toxicity

June 11, 2025

Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025

February 25, 2025

BioCentury Article | Emerging Company Profile

Lifordi: Applying ADCs to Autoimmune Conditions

January 9, 2025

Lifordi Immunotherapeutics Appoints Matthew W. McClure, M.D., as Chief Medical Officer

September 27, 2024

Lifordi Named Winner of Endpoints 11 as Developer of Antibody Drug Conjugates for Autoimmune and Inflammatory Diseases

To watch the Endpoints 11 award ceremony, register here. Lifordi’s acceptance is at the ~16:30 mark.

EVENTS

October 26, 2025, 11:30am
American College of Rheumatology Convergence 2025

Poster Session: Rheumatoid Arthritis - Treatment Poster I

September 15, 2025, 3:00pm
Stifel 2025 Virtual Immunology and Inflammation Summit Forum

September 18, 2024, 1:00pm
Stifel 2024 Virtual Immunology and Inflammation Summit

PRESENTATIONS

October 26, 2025

ACR 2025 Poster: LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates

June 11, 2025

EULAR 2025 Poster: Immune-Targeted Glucocorticoid ADC for the Treatment of Autoimmune and Inflammatory Diseases